Lates News

On June 16, Fosun Pharma and Teva Pharmaceutical Industries Ltd. ("Teva") jointly announced that they have reached a strategic cooperation agreement through their respective subsidiaries for the development of the investigational drug anti-PD1-IL2 ATTENUKINE therapy TEV-56278. According to the agreement, in order to accelerate the development of clinical data, Fosun Pharma will obtain exclusive development, production, and commercialization licenses for TEV-56278 in China (including Hong Kong, Macau, and Taiwan) as well as certain Southeast Asian countries. Teva will retain the rights for the development, production, and commercialization of TEV-56278 in other regions worldwide.